KRTX Live signals | Maximize Profits with Getagraph.com

BUY 58083 min ago

@ $329.82

Issued: 15 Mar 2024 @ 11:55

Return: 0.00%

Previous signal: Mar 15 - 09:30

Previous signal: Sell

Return: -0.04 %

Live Chart Being Loaded With Signals

Commentary (15 Mar 2024 @ 16:00):

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions...

Stats
Today's Volume	1.28M
Average Volume	971 825
Market Cap	12.60B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-3.00 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-28.09
ATR14	$4.03 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Wheadon David E.	Sell	990	Common Stock
2024-03-18	Wheadon David E.	Sell	25 000	Option (right to buy)
2024-03-18	Wheadon David E.	Sell	8 500	Option (right to buy)
2024-03-18	Wheadon David E.	Sell	5 000	Option (right to buy)
2024-03-18	Wheadon David E.	Sell	1 904	Option (right to buy)

INSIDER POWER
-93.83
Last 100 transactions
Buy: 115 486 \| Sell: 3 548 924

Volume Correlation

Long: 0.41 (neutral)

Short: 0.44 (neutral)

Signal:(75.401) Neutral

Karuna Therapeutics Inc Correlation

10 Most Positive Correlations
CNSP	0.813

10 Most Negative Correlations
OKTA	-0.829

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Karuna Therapeutics Inc Correlation - Currency/Commodity

0.82
( strong )

0.77
( moderate )

0.27
( neutral )

0.42
( neutral )

-0.62
( weak negative )

-0.82
( strong negative )

Karuna Therapeutics Inc Financials

Annual	2023
Revenue:	$654 000
Gross Profit:	$-1.05M (-160.09 %)
EPS:	$-11.73

Q4	2023
Revenue:	$0
Gross Profit:	$-447 000 (0.00 %)
EPS:	$-3.01

Q3	2023
Revenue:	$0
Gross Profit:	$-458 000 (0.00 %)
EPS:	$-3.16

Q2	2023
Revenue:	$0
Gross Profit:	$-469 000 (0.00 %)
EPS:	$-2.75

Financial Reports:

No articles found.

Karuna Therapeutics Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.